Davis Capital Management Alkermes Plc. Call Options Transaction History
Davis Capital Management
- $126 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALKS
# of Institutions
363Shares Held
182MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$895 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$583 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$400 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$389 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$282 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.05B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...